Trials / Terminated
TerminatedNCT05788289
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
Phase 2 Study of Tafasitamab and Lenalidomide in Relapsed or Refractory Mantle Cell Lymphoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if the combination of tafasitamab and lenalidomide is an effective treatment for relapsed or refractory Mantle Cell Lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tafasitamab | Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles. Each cycle is 28 days in length. |
| DRUG | Lenalidomide | Lenalidomide will be self-administered by patients orally on days 1-21 of each 28-day cycle of induction (cycles 1 through 12). |
Timeline
- Start date
- 2023-03-14
- Primary completion
- 2024-08-01
- Completion
- 2024-08-01
- First posted
- 2023-03-28
- Last updated
- 2025-05-25
- Results posted
- 2025-04-20
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05788289. Inclusion in this directory is not an endorsement.